| Cas No.: | 1229453-99-9 |
| 名称: | 5-({6-[(methylamino)methyl]pyrimidin-4-yl}oxy)-N-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]-1H-indole-1-carboxamide |
| 别名: | LHA510;LHA 510 |
| SMILES: | N(C(NC1C=C(C(F)(F)F)N(C)N=1)=O)1C2=C(C=C(OC3C=C(CNC)N=CN=3)C=C2)C=C1 |
| 分子式: | C20H18F3N7O2 |
| 分子量: | 445.406 |
| 纯度: | |
| 保存条件: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | |
| In Vivo: | |
| In Vitro: | |
| References: | A novel potent, selective VEGFR-2 (KDR) inhibitor with IC50 of 17.4 nM in cell-based assays; exhibits <10% remaining kinase activity against only 13 wildtype kinases, CSF1R, Kit, PDGFRα, PDGFRβ, VEGFR1, VEGFR2, VEGFR3, Fms, DDR1, DDR2, TIE1, and ABL1 in a panel of >400 kinases; demonstrates potency and efficacy in rodent CNV models, limited systemic exposure after topical ocular administration, multiple formulation options, and an acceptable rabbit ocular PK profile. |
| Kinase Assay: | |
| Cell Assay: | |
| Animal Administration: | |
| References: |
MSDS
COA
| LOT NO. | DOWNLOAD |
|
|
|
| 2018-0101 |
|
